AbbVie reported a robust fourth-quarter performance, with operational sales increasing by 6.1% to $15.1 billion. The company’s psoriasis treatment Skyrizi saw a staggering 59% sales increase to $3.78 billion, while Rinvoq sales hit $1.8 billion, up 47%. The positive outlook for 2025 exceeded analyst predictions, contributing to a 7% stock surge. This comes after a difficult period following the failure of their schizophrenia drug, emraclidine, but the success of recently launched immunology drugs provides a positive counterbalance, positioning AbbVie for substantial future revenue growth.
AbbVie's fourth-quarter results exceeded expectations, highlighting strong performance in immunology drugs Skyrizi and Rinvoq, with projected combined sales of $31 billion by 2029.
Despite past setbacks with the emraclidine schizophrenia drug trial, AbbVie has regained momentum, primarily due to impressive sales growth in its key immunology products.
Collection
[
|
...
]